EpiSign

EpiSign is a clinical diagnostic platform specializing in the identification of rare neurodevelopmental disorders through DNA methylation analysis. Developed by researchers at London Health Sciences Centre and Western University, the technology utilizes a comprehensive database of epigenetic signatures to diagnose conditions that often remain undetected by traditional genetic sequencing. The platform provides a first-in-class clinical test that can identify over 100 distinct epigenetic syndromes, offering a higher diagnostic yield for patients with complex clinical presentations. EpiSign is currently commercialized through a network of licensed clinical laboratories globally, including major institutions like the Mayo Clinic and Greenwood Genetic Center.